Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab

ConclusionsOccurrence of immune-related adverse events and changes in neutrophil-to-lymphocyte ratio during nivolumab treatment may help predict the therapeutic efficacy of nivolumab monotherapy for unresectable or recurrent gastric cancer.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research